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Abstract: Hypertensive diabetes individuals are at higher risk for cardiovascular events and 
progression to end stage renal disease. Several well conducted clinical trials indicate that 
aggressive treatment of hypertension in individual with diabetes reduces these complications. 
Combinations of two or more antihypertensive drugs are frequently required to reach the target 
blood pressure and to improve the cardiovascular and renal outcomes in these patients. There 
are physiological and clinical rationales for renin-angiotensin system blockade in hyperten-
sive diabetics. Trandolapril/verapamil sustained released (SR) is a ﬁ  xed-dose combination 
of trandolapril and a sustained release formulation of verapamil and indicated in treatment of 
hypertension in patients who require more than one drug to reach target blood pressure. The 
antihypertensive efﬁ  cacy of trandolapril/verapamil SR has been evaluated extensively in large 
trials. In the INVEST trial, a verapamil SR-based treatment strategy that included trandolapril 
in most patients was effective in reducing the primary outcome in hypertensive patients with 
coronary artery disease. The new onset of diabetes was also signiﬁ  cantly lower in the verapamil 
SR/trandolapril treatment group in comparison with those on the atenolol/hydroclorothiazide 
treatment group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) 
documented that in hypertensive diabetes and normoalbuminuria, trandolapril plus verapamil or 
trandolapril alone delayed the onset of microalbuminuria independent of their blood pressure-
reducing effect. Thus, trandolapril/verapamil is an effective option for treatment of hypertensive 
diabetes patients requiring more than one agent to achieve target blood pressure.
Keywords: diabetes mellitus, hypertension, trandolapril, verapamil SR
Introduction
Diabetes is a rapidly growing health problem worldwide, related in part to improved 
living conditions and increasing rate of obesity (World Health Report 2003). It is 
estimated that approximately 5% of people in the general population of most indus-
trialized societies have diabetes mellitus and that an additional 3%–5% have either 
undiagnosed diabetes or impaired glucose tolerance. According to the World Health 
Organization, worldwide the number of people living with diabetes is projected to in-
creased from 172 million in 2000 (prevalence: 2.8%) to 366 million (prevalence: 4.4%) 
in 2030 (Wild et al 2004). Hypertension is a common co-morbid condition in diabetes 
and found in 20%–60% of patients with diabetes (American Diabetes Association 
2004). Prevalence of hypertension in the diabetic population is 1.5–3 times higher 
than in the age- and weight-adjusted non-diabetic group (Hypertension in Diabetes 
Study 1993). In type 2 diabetes, hypertension is often present as a part of metabolic 
syndrome, while in type 1 diabetes it may herald the onset of diabetic kidney disease. 
The hypertensive diabetic individuals are at a 2- to 4-fold greater risk of vascular 
complications, such as coronary artery disease, cerebrovascular accident, and death 
compared with age-matched control subjects and with the patients with type 2 diabetes Vascular Health and Risk Management 2007:3(4) 454
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mellitus but normal blood pressure. Similarly, they also have 
a 7-fold greater risk of progression to end stage renal disease 
(ESRD) (Perneger et al 1994; Beckman 2002). Reduction 
of high blood pressure reduces cardiovascular morbidity 
and mortality and delays the progression to ESRD. Indeed, 
various studies has shown that lowering blood pressure in 
high risk patients with diabetes reduces overall mortality 
(Haansoon et al 1998; UK Prospective Diabetes Study Group 
1998; Waeber 2003), death from stroke (Curb 1996), and 
cardiovascular events (Haansoon et al 1998; Tatti et al 1998) 
and slows the progression of renal disease in patients with 
type 2 diabetes mellitus (Brenner et al 2001; Parving et al 
2001; Berl et al 2003). Consensus statements and guidelines 
from various international authorities recommend initiation 
of pharmacological therapy with the goal of reduction of 
blood pressure to <130/80 mmHg (National Kidney Foun-
dation 2002; American Diabetes Association 2004) and/or 
<130/85 mmHg (Chobanian et al 2003) and consider dia-
betes as a risk equivalent similar to history of myocardial 
infarction (Chobanian et al 2003) because of the increased 
risk of cardiovascular events in these groups of patients. 
Evidence has shown that achieving this goal requires 
multiple drug antihypertensive therapy. Indeed, because 
of the fact that blood pressure reduction to recommended 
goal is often difﬁ  cult to achieve with monotherapy, the Joint 
National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure (JNC) (Chobanian 
et al 2003) suggests initial use of a two-drug combination, 
even in non-diabetic patients. Greater efﬁ  cacy is likely to 
be achieved when two or more antihypertensive agents with 
complementary modes of action are used to reduce blood 
pressure. This approach is also likely to reduce adverse 
effects of drugs, as both drugs can be given at a lower dose 
than either drug as monotherapy. In addition, combination 
of two ﬁ  xed-dose agents in a single capsule or tablet is ex-
pected to increase compliance (Sica 2002). In treatment of 
hypertensive diabetic patients adverse effects on metabolic 
control and insulin sensitivity is an issue to be considered. 
Calcium channel blockers and angiotensin-converting 
enzyme (ACE) inhibitors are considered lack of undesirable 
effect on glucose tolerance and insulin sensitivity; rather 
potentially improve insulin sensitivity (Sutter et al 1995; 
Holzgreve et al 2003).
Trandolapril/verapamil sustained released (SR) is a ﬁ  xed-
dose combination of trandolapril, and a sustained release 
formulation of verapamil (Abbott Laboratories 2003a). 
This article provides an overview of trandolapril/verapamil 
SR in the treatment of hypertensive diabetic patients and 
its effectiveness on reduction of microalbuminuria in 
hypertensive type 2 diabetic patients.
Pharmacodynamics properties
of trandolapril/verapamil SR
Trandolapril is an ethyl ester pro-drug of a nonsufyldril ACE 
inhibitor. It is converted to trandolaprilat by de-esterﬁ  cation. 
The active metabolite is 8 times more active as an inhibitor of 
ACE. Trandolapril inhibits the circulating and tissue ACE, 
leading to inhibition of conversion of angiotensin I to 
angiotensin II that results in a decrease in vasoconstriction, 
a decrease in aldoesteron secretion, and an increase in 
plasma renin (Muijsers et al 2002). Although, the principal 
mechanism of trandolapril is thought to be through the 
renin-angiotensin-aldosteron system, trandolapril is effective 
in low renin hypertension also (Abbott Laboratories 2003a). 
Verapamil, an L-type calcium channel blocker, exerts its 
pharmacological effect by blocking the calcium influx 
through calcium channel. This effect leads to dilatation of 
peripheral vessels, thereby decreasing systemic vascular 
resistance and blood pressure. It also dilates coronary blood 
vessels (Muijsers et al 2002).
Trandolapril/verapamil SR is an oral ﬁ  xed-dosed com-
bination of slow release verapamil hydrochloride, and an 
immediate-release formulation of trandolapril. It is indicated 
in the treatment of hypertension in a patient who requires 
more than one agent to achieve blood pressure target. Studies 
of verapamil with various ACE inhibitors indicate that the 
combination should be the therapy of choice in hypertensive 
patients with diabetes or nephropathy (Haegert et al 1987; 
Bakris et al 1992; Choi et al 2005). The complementary phar-
macological action of ACE inhibitor and calcium antagonist 
on efferent and afferent arterioles also results in a beneﬁ  cial 
effect on glomerular function. It also exerts additive inhibi-
tion of sodium reabsorption via inhibition of aldosterone 
secretion and a direct tubular effect. The combination of 
trandolapril and verapamil may also provide additional 
beneﬁ  t in inducing the regression of left ventricular hyper-
trophy (Widimsky 2000; Raynolds et al 2005). Combination 
therapy also signiﬁ  cantly increases left ventricular ejection 
fraction and left ventricular wall motion index in hypertensive 
patients (Widimsky 2000) and duration of exercise time in 
patients with coronary heart disease and left heart failure. 
It also leads to an improvement in the ratio of exercise to 
rest rate-pressure product and a decrease in the number of 
angina attacks (Widimsky 2000; Raynolds et al 2005). The 
trandolapril/verapamil treatment was also found to reduce 
incidence of cardiac events in comparison with trandolapril Vascular Health and Risk Management 2007:3(4) 455
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therapy in patients with congestive heart failure after acute 
myocardial infarction (Hansen et al 1997). The combination 
therapy signiﬁ  cantly reduced death, re-infarction, unstable 
angina, or readmission due to increasing congestive heart 
failure. Similarly, the combination therapy was also 
found to have a positive effect on aortic elastic properties 
(Breithaupt-Grogler et al 1998; Topouchian et al 1999; 
Romos et al 2001). In the patients with hypertension and 
diabetes mellitus, trandolapril/verapamil combination 
does not adversely affect glucose and lipid metabolism 
(Fernández et al 1996; Schneider et al 1996; Holzgreve et al 
2003). Rather, data from short-term and long-term studies 
indicate that ACE inhibitors may actually improve insulin 
sensitivity and decrease the risk of hypertensive diabetic 
patients (Bakris et al 1992; The Heart Outcome Prevention 
Evaluation Study Investigators 2000; Sowers et al 2000). As 
worsening/inadequate glycemic control has been shown to be 
a strong risk factor for both micro- and macro-vascular com-
plications in diabetes, antihypertensive drug without adverse 
effects on glucose metabolism, such as trandolapril/verapamil 
combination, in hypertensive diabetic patients offers an 
advantage provided blood pressure control is adequate.
Pharmacokinetics trandolapril/
verapamil SR 
There is no known kinetics interaction between verapamil 
and trandolapril or trandolaprilate. The single agent pharma-
cokinetic parameters of these two drugs should be applicable 
to a combination product also. However, when administered 
concomitantly, trandolapril increases the peak plasma concen-
tration (Cmax) of verapamil and norverapamil but time to Cmax 
(Tmax) remains unaffected (Abbott Laboratories 2003a).
Trandolapril component
The pharmacokinetic parameters of single and multiple 
doses of trandolapril in healthy volunteers are summa-
rized in Table 1. However, there are very few data on 
pharmacokinetics of trandolapril/verapamil in patients with 
hypertension, more so for the hypertensive diabetic patients. 
Most of the information is derived from the manufacturer’s 
information (Abbott Laboratories 2002b, 2003a). After oral 
administration trandolapril is absorbed rapidly. Although, 
absorption is 40%–60%, absolute bioavailability of trandol-
april is 10% of the oral dose. The absolute bioavailability 
of trandolaprilate is 70% (Abbott Laboratories 2003b). 
Food does not interfere with absorption of the drug. Cmax of 
trandolapril after a single oral dose is proportional to the dose 
administered and occurs at around a half to 1 hour (Bevan 
et al 1993; Arner et al 1994; Lenfant et al 1994). After the oral 
dose the Cmax of the trandolaprilate is dose proportional, but 
inversely related. Tmax ranges from 4 to 8 hours (Bevan et al 
1993; Arner et al 1994; Lenfant et al 1994). The elimination 
half-life (t1/2) is less than 1 hour for trandolapril, whereas it is 
about 75 hours for trandolaprilate (Bevan et al 1993; Arner 
et al 1994; Lenfant et al 1994; Siepman et al 1997). Plasma 
protein binding of both trandolapril and trandolaprilate is 
more than 80% (Abbott Laboratories 2003b).
Trandolapril is de-esteriﬁ  ed to trandolaprilate and this 
biotransformation takes place mainly in liver (Abbott Labo-
ratories 2003b). Steady state is reached after about 4 days 
with multiple oral doses. The effective half-life calculated 
from accumulation is 16–24 hours (Abbott Laboratories 
2003b). The drug is eliminated from the body predominantly 
(2/3rd) by fecal route, and one third in the urine. Most of the 
radioactivity of orally administered radiolabeled trandolapril 
is excreted after 48 hours and elimination is complete (~99%) 
by 7 days (Wiserman et al 1994)
Renal clearance of trandolapril and trandolaprilate exhibit 
a linear correlation with creatinine clearance and the clearance 
of trandolapril and trandolaprilate decrease with decreasing 
renal function (Abbott Laboratories 2002b, 2003b). Two 
studies have evaluated the pharmacokinetics of trandolapril 
and trandolaprilate in patients with chronic renal failure and 
compared that with volunteers (Bevan et al 1993; Danielson 
Table 1 Pharmacokinetic properties of trandolapril (T) in healthy volunteers
Dosage Duration Cmax
a (mg/mL)  Tmax
b (hour)  AUC ng/mL (hour)  T1/2 (hour)
T 0.5 mg  Single dose  0.43 (0.1)*  1#  0.4 (0.11)*  0.71 (0.08)* 
T 1 mg  Single dose  0.86 (0.1)*  0.5#  0.95 (0.15)*  0.74 (0.09)*
T 2 mg  Single dose  1.68 (0.33)*  0.5#  1.86 (0.3)*  0.68 (0.05)*
T 4 mg  Single dose  3.32 (0.56)*  0.5#  3.64* (0.44)*  0.76 (0.13)*
T 2 mg  qd for 10 days  3.19 (0.33)*  1#  3.67 (0.97)*  0.68 (0.07)*
aCmax, peak plasma concentration. 
bTmax, time to Cmax
*Mean.
# Median.Vascular Health and Risk Management 2007:3(4) 456
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et al 1994). Compared with normal subjects, the plasma con-
centration of trandolapril and trandolaprilate are approximately 
2-fold greater and renal clearance is reduced by about 85% 
in patient with creatinine clearance below 30 mL/min and 
in patients on hemodialysis (Abbott Laboratories 2003b). In 
people with moderate to severe hepatic impairment the plasma 
concentration of trandolapril is increased by 9-fold. The plasma 
concentration of trandolaprilate is also increased but to a lesser 
extent. However, inhibition of ACE activity was not affected 
(Abbott Laboratories 2002b, 2003b). In people above 65 
years of age, the bioavailability of trandolapril is increased by 
25%. However, dose adjustment is not recommended (Abbott 
Laboratories 2003b; Raynolds et al 2005).
Verapamil component 
Similar to the immediate-release formulation, approximately 
90% of the administered sustained released formulation is 
absorbed (Abbott Laboratories 2003a). However, the rate 
of absorption is delayed. Because of ﬁ  rst-pass metabolism 
of verapamil, the absolute bioavailability of the drug ranges 
from 20% to 35% (Abbott Laboratories 2002a, 2003a). 
Following administration of verapamil SR 240 mg, the 
mean peak plasma concentration is reached at 5 hours, while 
that of its active metabolite norverapamil in around 6 hours 
(Abbott Laboratories 2002a, 2003b). Steady state plasma 
concentration is reached 3–4 days after multiple oral doses 
of verapamil. Verapamil is 90% bound to plasma proteins 
(Abbott Laboratories 2003b). Verapamil undergoes extensive 
ﬁ  rst-pass metabolism in the liver by the P450 cytochrome 
system (Abbott Laboratories 2002b). Out of 12 metabolites 
of verapamil, except the primary active metabolite nor-
verapamil, all other metabolites are present in trace amount 
(Abbott Laboratories 2002a). The mean elimination half-life 
is around 8 hours following multiple doses administration 
(Abbott Laboratories 2002b). Most of the administered 
verapamil is excreted as metabolites in urine (70%) and 
feces (16%). Three to four percent of administered dose is 
excreted unchanged (Abbott Laboratories 2003b). As vera-
pamil undergoes extensive ﬁ  rst-pass metabolism, presence of 
hepatic dysfunction increases the bioavailability and elimi-
nation half-life of verapamil (Abbott Laboratories 2002b). 
In patient with severe hepatic dysfunction, the clearance is 
reduced to 30%, while terminal elimination half-life is pro-
longed by 4–16 hours (Abbott Laboratories 2002a, 2003a). 
The pharmacokinetics and elimination of verapamil is not 
altered by impairment of kidney function (Abbott Laborato-
ries 2002a; Danielson et al 1994). Compared with younger 
subjects, the bioavailability of verapamil and its metabolite 
norverapamil is increased by 87% and 77%, respectively, in 
the elderly (Abbott Laboratories 2003a).
The trandolapril/verapamil SR combination has not been 
evaluated in subjects with hepatic or renal impairment. In 
Europe, it is contraindicated in patients with creatinine clear-
ance of less than 10 mL/min, patients receiving hemodialysis, 
and patients with severe hepatic impairment, cirrhosis, and 
ascites (Abbott Laboratories 2002b, 2003a), while in the US, 
caution is required to use the combination in patients with 
hepatic impairment (Abbott Laboratories 2003a). The special 
instructions for the individual compounds of the combination 
of trandolapril and verapamil SR apply to the combination 
product also (Abbott Laboratories 2002b, 2003a).
In the elderly, systemic availability of trandolapril/vera-
pamil SR is higher than in younger subjects; therefore blood 
pressure of some elderly patients might be lowered more than 
that of younger subjects (Abbott Laboratories 2002b)
Drug interactions
There are several important pharmacodynamic and pharma-
cokinetic interactions between these two classes of drugs, as 
with a number of other drugs (Abbott Laboratories 2002a, 
2003b; Sweetman 2005). Although co-prescription of tran-
dolapril/verapamil SR with potassium-sparing diuretics or 
supplementation of potassium may cause hyperkalemia due 
to trandolapril, the use of dantrolin with verapamil may cause 
malignant hyperthermia, and is therefore not recommended 
(Abbott Laboratories 2002b, 2003b; Sweetman 2005). A 
numbers of drugs have a potential pharmacodynamic inter-
action with trandolapril or verapamil SR; therefore, close 
monitoring or dose adjustment is needed (Abbott Laborato-
ries 2002a; Abbott Laboratories 2002b; Abbott Laboratories 
2003b; Abbott Laboratories 2003b). Few important pharma-
cokinetic interactions are tabulated (Table 2). Trandolapril 
and its active metabolite do not have clinically signiﬁ  cant 
interactions with furosemide and warfarin (Abbott Labo-
ratories 2003b). The details of the pharmacodynamic and 
pharmacokinetic interactions of the combination may be 
found in the manufacturer’s prescribing information (Haegert 
et al 1987; Abbott Laboratories 2002b; Abbott Laboratories 
2003b; Sweetman  2005). 
Therapeutic efﬁ  cacy
The antihypertensive efficacy of trandolapril/verapamil 
SR has been evaluated extensively in large randomized, 
double-blind or open-labeled blinded endpoint, multicenter 
studies (de leeuw PW et al 1997; DeQuattro V 1997; The 
Veratran study group 1997; Viskoper 1997; Kalberge et al Vascular Health and Risk Management 2007:3(4) 457
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2000; Papine et al 2003). In the INVEST trial (Papine et al 
2003) a verapamil SR-based treatment strategy that included 
trandolapril in most patients was effective in reducing the 
primary outcome in hypertensive patients with coronary 
artery disease (Papine et al 2003). Several subgroup analy-
ses of INVEST (Bakris et al 2004; Mancia et al 2004; Reid 
et al 2005) have been published. Of note, the risk of new 
onset diabetes was lower in those receiving verapamil SR 
and trandolapril therapy. INVEST was a randomized, open-
label, blinded, endpoint study that involved 22,576 patients 
aged  50 years with hypertension and coexisting coronary 
artery disease (CAD). A total of 16,176 patients were non-
diabetic hypertensives with CAD at the time of entry to the 
trial. The primary outcome – all-cause mortality, non-fatal 
stroke, and non-fatal myocardial infarction – was compared 
between two treatment strategies: a calcium channel blocker 
(verapamil SR)-based strategy and beta blocker (atenolol)-
based startegy. As most older hypertensives need two or more 
antihypertensive drugs to control blood pressure, INVEST 
was intended to compare the multidrug strategies rather than 
individual agents. To reach the blood pressure goals targeted 
according to JNC VI at the time of initiation of the trial, 
adding sequentially prespeciﬁ  ed antihypertensive medica-
tions to both treatment arms was allowed in the trial. The 
verapamil arm allowed for the addition of the ACE inhibitor 
trandolapril or of a co-formulated tablet containing verapamil 
SR and trandolapril. The diuretic hydrochlorothiazide could 
then be added if needed. The beta-blocker arm allowed 
for the addition of hydrochlorothiazide, with trandolapril 
added as required to reach goal. ACE inhibitor therapy was 
recommended for all patients with diabetes or renal disease, 
regardless of treatment strategy. 
Among the patients who did not have diabetes at baseline 
(8098 in the verapamil SR group and 8078 in the atenolol 
group), the new onset of diabetes was signiﬁ  cantly lower 
(7.03%) in the verapamil SR/trandolapril treatment group 
in comparison with those on the atenolol/hydroclorothiazide 
treatment group (8.23%) (Figure 1). Treatment with hydro-
chlorothiazide 25 mg daily was associated with new diabetes 
in both strategies, whereas increased exposure to the ACE 
inhibitor trandolapril in verapamil SR strategy appeared to be 
associated with more protection from the atenolol/hydrochlo-
rothiazide strategy (Abuissa 2005). However, it is difﬁ  cult 
to draw a conclusion about the contribution of any single 
agent because the trial was a comparison of both arms with 
more than one drug regimen (Alderman 2003). So it is also 
not possible to evaluate the independent role of verapamil in 
INVEST, and it cannot be excluded that the beneﬁ  t is driven 
by the trandolapril alone, as it is more likely that the ACE 
inhibitor prevents diabetes by blocking the renin angiotensin 
system. While antihypertensive treatment strategy in the 
diabetes cohort of the INVEST trial was compared between 
the verapamil SR-based (n = 3169) treatment arm and the 
atenolol-based (n = 3231) treatment arm, there was no sig-
niﬁ  cant difference in the primary outcome between these 
two treatment groups.
Table 2 Pharmacokinetic interaction between oral trandolapril or verapamil SR and other agents when administered concomitantly 
(only clinically relevant interactions are cited) 
Effects of verapamil-SR on pharmacokinetics of
Carbamazapine  Increases the plasma concentration of carbamazapin
Cyclosporine  Increases the serum concentration of cyclosporine
Digoxin  Increases the serum concentration of digoxin
Ethanol  Verapamil decreases the elimination of ethanol
Metoprololo/propanolol  Verapamil decreases the clearance
Quinidine  Increases the serum concentration of quinidine
Effects of trandolapril on
Lithium  Trandolapril (ACE inhibitors) increase serum concentration of lithium
Effects of other agents on verapamil SR pharmacokinetics
Cimetidine  Increase in verapamil clearance is possible
Erythromycin  Increases plasma level of verapamil due to inhibition of CYP3A4 inhibition
Grapefruit juice  Increases plasma concentration of verapamil
Phenobarbitone  Increases verapamil clearance
Rifampicine  Decreases verapamil bioavailability due to CYP3A4 induction
Ritonavir   Increases plasma level of verapamil due to inhibition of CYP3A4 inhibition
Effects of other agents on trandolapril pharmacokinetics
Antacids  Decreases the bioavailability of trandolaprilVascular Health and Risk Management 2007:3(4) 458
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Bakris et al (1998) reported for the first time that 
combination of a non-dihydorcalcium channel blocker 
(verapamil) with an ACE inhibitor (trandolapril) achieved bet-
ter proteinuria reduction in comparison with either agent alone 
in a randomized, open-labeled, parallel group study. Mean 
arterial pressure was lower by 3–4 mmHg in the combination 
group than in the group receiving either agent alone. The ef-
fect of combinations of antihypertensive drugs on metabolic 
control and albuminuria in type 2 diabetic patients has also 
been studied in the TRAVEND trial. The group of patients 
receiving the verapamil/trandolapril combination had better 
metabolic control than enalapril/hydrochlorothiazide group 
(0.45% difference in HbA1c levels; p = 0.04) (Fernández et al 
2001). The efﬁ  cacy related to reduction of albuminuria and 
blood pressure was comparable in both groups. 
A ﬁ  xed combination of trandolapril/verapamil was 
compared with trandolapril alone or placebo to attain the 
required blood pressure goal in previously untreated type 
2 diabetic patients presenting with either high normal 
blood pressure or ﬁ  rst stage of isolated hypertension in a 
randomized, double-blind, placebo-controlled, compara-
tive multicenter study (Ruilope et al 2004). A total of 393 
patients completed the study. Blood pressure reduction was 
better in patients treated with either trandolapril or ﬁ  xed 
combination of verapamil/trandolapril than in the placebo 
group. The mean difference in systolic blood pressure from 
placebo was 7.1 mmHg (3.3–10.9, 95% CI, p < 0.001) for 
trandolapril and 7.8 mmHg (3.9–11.6, 95% CI, p < 0.001) 
for the ﬁ  xed-dose combination group with no statistically 
signiﬁ  cant difference between the two groups. Combination 
treatment was also more effective in reducing the diastolic 
blood pressure than placebo. No signiﬁ  cant difference was 
found between the ﬁ  xed-combination verapamil/trandolapril 
and trandolapril with regards to control of systolic 
blood pressure, but diastolic blood pressure control was 
signiﬁ  cantly higher in the ﬁ  xed-combination verapamil/
trandolapril group (88%) when compared with trandolapril 
alone (79.1%) or placebo (63.5%).
The issues of metabolic effects of antihypertensive 
therapy on diabetic patients were also evaluated in various 
trials. There is increasing concern regarding the metabolic 
effects of antihypertensive drug therapy and their impact 
on cardiovascular risk reduction resulting from the treat-
ment of hypertension (Sowers 1995). Studies by Berne 
et al (1991) have indicated that ACE inhibitors improve 
glucose use and insulin sensitivity in hypertensive patients 
T 2 – Trandolapril 2 mg
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HT 25     – Hydrochlothiazide 25 mg
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Figure 1  Among the patients who did not have diabetes at baseline (8098 in the verapamil SR group and 8078 in the atenolol group) addition of trandolapril in verapamil 
SR strategy was associated with more protection from the development of new onset diabetes than that in the atenolol/hydrochlorothiazide strategy arm.  When tran-
dolapril 2 mg was added to verapamil 180 mg and trandolapril 4 mg to verapamil 240 mg the hazard ratio for development of new onset diabetes was 0.56 (0.98–1.64, 
conﬁ  dence interval [CI] 95%), and 0.58 ( 0.44–0.78, CI 95%) respectively. Vascular Health and Risk Management 2007:3(4) 459
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with type 2 diabetes. The metabolic, antihypertensive, and 
albuminuria-modifying effects of the trandolapril/verapamil 
combination compared with those of a β-blocker low-dose 
diuretic combination (atenolol/chlortalidone) in hypertensive 
type 2 diabetic patients was investigated in 2 separate studies 
(Schneider et al 1996; Ruilope 2002). The two approaches 
produced similar decrease in mean supine clinic blood 
pressure (BP), upright clinic BP, and ambulatory daytime 
BP. The trandolapril/verapamil combination was found to 
be metabolically neutral, while the atenolol/chlortalidone 
combination further aggravated insulin resistance. This 
indicates that the trandolapril/verapamil combination is a 
potentially valuable therapy for hypertension accompanying 
type 2 diabetes, since the beneﬁ  ts of the ACE inhibitor may 
be ampliﬁ  ed by providing superior BP control with added 
renal and cardiovascular protection. 
In a further study, in patients with hypertension and 
type 2 diabetes, the effects of either ﬁ  xed-dose combination 
of trandolapril/verapamil or a combination of atenolol/
clorthalidone, on glycosylated hemoglobin (HbA1c) and 
other metabolic parameters was evaluated. The trandolapril/
verapamil group had lower HbA1c concentration compared 
with patients treated with atenolol/chlortalidone (7.8 vs 8.6%; 
p = 0.001), demonstrating a signiﬁ  cantly more favorable pro-
ﬁ  le on glycemic control (Holzgreve et al 2003). The data of 
all these studies make the combination trandolapril/verapamil 
very attractive in hypertensive diabetic patients. 
The high prevalence of diabetes, the increased rate of car-
diovascular and renal complications, and the beneﬁ  cial effect 
of antihypertensive therapy make primary prevention efforts 
a high priority. Hypertensive diabetes individuals are at high 
risk of developing cardiovascular disease and progression to 
ESRD. Hypertension, in addition, to obesity, hyperglycemia, 
dyslipidemia, and microalbuminuria, is a component of the 
metabolic syndrome – a syndrome sustained by decreased 
insulin activity that almost invariably precedes or accom-
panies the onset of type 2 diabetes and is independently 
associated with excessive cardiovascular morbidity and 
mortality (Flack et al 1991). Now, numerous studies have 
documented that the albumin excretion in the urine above 
the normal range is clearly associated with heightened risk 
of cardiovascular events and further progression of kidney 
disease. Every year 2%–5% of the type 2 diabetic patients 
develop microalbuminuria (Gall 1997; Alder et al 2003) and, 
unlike type 1 diabetes mellitus, it is seldom reversible in type 
2 diabetic patients and progresses to overt proteniuria in 
20%–40% of patients (Mogensen 1984; Nelson et al 1991). 
Forty to ﬁ  fty percent of patients with type 2 diabetes having 
microalbuminuria eventually die of cardiovascular disease 
(Alder et al 2003). Therefore, it is quite reasonable to target 
the treatment to modify the development of microalbuminuria 
at early stage of diabetes, as well as control blood pressure 
in hypertensive diabetes to limit the cardiovascular and renal 
disease. The Bergamo Nephrologic Diabetes Complications 
Trial (BENEDICT [Ruggenenti et al 2004]) was designed to 
test the hypothesis that combination therapy with the ACE 
inhibitor trandolapril and non-dihydropyridine calcium chan-
nel blocker verapamil reduced the incidence of persistent 
microalbuminuria in hypertensive type 2 diabetic patients 
with no clinical evidence of diabetic nephropathy. The 
secondary objectives involved comparisons of trandolapril 
or verapamil with placebo in providing renal protection in 
hypertensive diabetic patients.
In the BENEDICT study a total of 1204 patients with 
hypertension (systolic or diastolic blood pressure more than 
130 or 85 mmHg, respectively, or concomitant antihyperten-
sive therapy), type 2 diabetes and normal urinary excretion 
(<20 mg/min in at least 2 of 3 consecutive overnight urine 
collections) were randomly assigned, using 2 × 2 factorial 
design, to receive in a double blind manner for at least 3 
years one of the following study drugs: I, a non-dihydro-
pyridine calcium channel blocker (ndCCB): verapamil SR, 
240 mg/day; II, an ACE inhibitor: trandolapril 2 mg/day; 
III, the combination of verapamil SR, 180 mg/day plus 
trandolapril 2 mg/day: VeraTran; and IV, placebo. The 
target blood pressure after randomization and throughout 
the whole study period was less than 130/80 mmHg for all 
the treatment groups. Other antihypertensive drugs (with 
the exception of renin-angiotensin system inhibitors and 
ndCCBs different from the study drugs) could be used to 
achieve and maintain systolic and diastolic blood pressure 
consistently below 140/90 mmHg (subsequently amended to 
below 130/80 mmHg at randomization and below 120/80 on 
follow up (The BENEDICT Group 2003; Ruggenenti et al 
2004). Baseline characteristics and simultaneous treatments 
of patients randomized in the four treatment groups were 
comparable. Patients were to be maintained in metabolic 
control (target HbA1c <7%). Patients were excluded if they 
had concomitant non-diabetic renal disease or heart failure 
(NYHA-IV or on ACE inhibition therapy), cardiovascular 
events (stroke, transient ischemic attack, unstable angina) in 
the last 3 months before randomization, severe hypertension 
(diastolic blood pressure >115), systemic diseases, or any 
major clinical condition that jeopardize study participation. 
Patients with speciﬁ  c contraindication to the study drug were 
also excluded. Vascular Health and Risk Management 2007:3(4) 460
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The BENEDICT study found that over 4 years of 
follow-up, trandolapril alone, or trandolapril/verapamil 
SR (VeraTran) delayed the onset of microalbuminuria by a 
factor of 2.6 and 2.1, respectively, while verapamil had no 
signiﬁ  cant effect (Ruggenenti et al 2004). Thus the incidence 
of microalbuminuria versus placebo was reduced by 60% 
(hazard ratio [95% CI]: 0.39 [0.21–0.73]) with VeraTran 
and by 50% with trandolapril (Hazard ratio [95% CI]: 0.49 
[0.27–0.90]), but was not appreciably affected by verapamil 
(Figure 2). This indicates that the apparent advantage of 
ACE inhibitors (trandolapril in BENEDICT) over other 
antihypertensive agents includes also a protective effect 
on the kidney against the development of microalbumin-
uria, at least in type 2 diabetic patients. Moreover, ﬁ  nding 
that this effect was signiﬁ  cant even after adjustment for 
baseline and follow-up systolic and diastolic blood pres-
sure provided evidence of a speciﬁ  c renoprotective effect 
of ACE inhibition therapy against the development of 
microalbuminuria which was independent of the level of 
achieved blood pressure control. 
Recently the post-hoc analysis of the BENEDICT trial 
was reported (Ruggenenti et al 2006). Of 1204 patients in 
the original study cohort, 1180 patients were included in 
the post-hoc analysis. Twenty-four patients were excluded 
because either they reached an endpoint, stopped regular 
study follow-up or blood pressure recording was inadequate 
for the analysis. Overall, the systolic blood pressure was 
decreased 6.5 ± 7.63% and diastolic blood pressure was 
decreased 6.4 ± 7.47% from baseline to follow-up. Baseline 
mean arterial pressure (MAP) and pulse pressure were 
108.6 ± 8.33 mmHg and 63.3 ± 12.64 mmHg: they decreased 
by 6.5 ± 6.83% and 5.3 ± 14.70%, to 101.2 ± 6.47/58.9 ± 9.99 
mmHg on follow-up. The ﬁ  ndings from a post-hoc analysis 
suggest that in patients with type 2 diabetes and hypertension, 
effective blood pressure reduction has a specific and 
independent protective effect against the development of 
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Figure 2  The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a multicenter double-blind, randomized study designed to assess whether the angiotensin 
converting enzyme inhibitor trandolapril and the non-dihydropyridine calcium-channel blocker verapamil, alone or in combination, prevent microalbuminuria in subjects 
with hypertension, type 2 diabetes mellitus, and normal urinary albumin excretion. The Kaplan-Meier curves show the percentages of subjects with microalbuminuria during 
treatment with trandolapril/verapamil or placebo. The difference between the two groups adjusted for pre-speciﬁ  ed baseline covariates was signiﬁ  cant (p = 0.01) according 
to the accelerated failure (A.F.)-time model.
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microalbuminuria. Nevertheless, trandolapril had a further 
protective effect, in particular when blood pressure was 
poorly controlled, whereas the ndCCB therapy was ineffec-
tive at any level of achieved blood pressure (Figure 3). The 
ﬁ  nding that the risk of developing microalbuminuria was not 
associated with baseline blood pressure provided consistent 
evidence that the lower incidence of microalbuminuria ob-
served with more effective blood pressure reduction reﬂ  ected 
a beneﬁ  t of treatment and not simply less severe hypertension 
at study entry (Figure 4). Therefore, these results extend to the 
very early stages of diabetic renal disease previous evidence 
of a renoprotective effect of blood pressure control in people 
with diabetes and established nephropathy (Mogensen 1976; 
Dillon 1993; Bakris et al 2003; Pohl et al 2005; Remuzzi 
et al 2006). Of interest, patients with systolic, diastolic, 
mean blood pressure, and pulse pressure reduction above 
the medians compared with those with corresponding blood 
pressure reductions below the medians, were more frequently 
on ACE inhibitor therapy with trandolapril/verapamil or 
trandolapril alone and, on the contrary, were less frequently 
on treatment with concomitant antihypertensive medications 
such as diuretics, betablockers, ndCCBs, and sympatholytic 
agents (Table 3). The risk reduction achieved by ACE inhibi-
tor therapy in patients with systolic, MAP, and pulse pressure 
below the median was signiﬁ  cant even after adjustment for 
baseline covariates and concomitant treatment with ndCCBs. 
A similar trend was observed for diastolic blood pressure. 
A major practical problem, however, is that the recom-
mended target of 130 mmHg for systolic blood pressure 
(Chobanian et al 2003) is seldom achievable in patients with 
type 2 diabetes, even when several blood-pressure-lowering 
medications are used in combination (Brenner et al 2001; Berl 
et al 2003; Ruggenenti et al 2004, 2006). Sixty-two percent of 
BENEDICT patients received one or more antihypertensive 
Figure 3  Patients who developed microalbuminuria throughout the study period of the BENEDICT trial according to follow-up systolic blood pressure (SBP). These are 
patients with type 2 diabetes, arterial hypertension, and normoalbuminuria at baseline. Effective SBP reduction below the median (<139.16 mmHg) has speciﬁ  c and indepen-
dent protective effects against the development of microalbuminuria. The risk reduction for microalbuminuria that was achieved by angiotensin converting enzyme inhibitor 
(ACEi) therapy in patients with follow-up SBP above the median (>139.16 mmHg) was highly signiﬁ  cant even after adjustment for baseline covariates and concomitant treat-
ment with non-dihydropyridine calcium channel blockers. Thus ACEi therapy had a further protective effect, in particular when SBP was less effectively controlled (inset).Vascular Health and Risk Management 2007:3(4) 462
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drugs in addition to the study drugs and all of them were 
recommended a low sodium intake. Despite this, only 14% 
of them achieved a systolic blood pressure of 130 mmHg or 
less. However, of note the highest proportion of patients on 
target was observed among those on combined trandolapril/
verapamil treatment who, notably, less frequently required 
concomitant treatment with other antihypertensive medica-
tions. This is of great signiﬁ  cance as hypertension is an 
independent and strong risk factor for cardiovascular disease 
events and renal disease progression in diabetic patients with 
Table 3 Number (%) of patients on different antihypertensive treatments on trial according to systolic blood pressure (SBP), diastolic 
BP (DBP), mean arterial pressure (MAP), and pulse pressure reduction above or below the median
    Systolic BP      Diastolic BP      MAP      Pulse pressure 
 below  above  below  above  below  above  below  above 
ACEi YES  319 (53.9)  273 (46.4)*  323 (54.6)  269 (45.8)**  316 (53.3)  276 (47.0)*  317 (53.6)  275 (46.8)*
ndCCB YES  293 (49.5)  297 (50.5)  300 (50.7)  290 (49.3)  303 (51.1)  287 (48.9)  283 (47.8)  307 (52.2)
VeraTran  158 (26.7)  135 (23.0)  157 (26.5)  136 (23.1)  160 (27.0)  133 (22.7)  153 (25.8)  140 (23.8)
Trandolapril  161 (27.2)  138 (23.5)  166 (28.0)  133 (22.6)*  156 (26.3)  143 (24.4)  164 (27.7)  135 (23.0)
Verapamil  135 (22.8)  162 (27.6)  143 (24.2)  154 (26.2)  143 (24.1)  154 (26.2)  130 (22.0)  67 (28.4)*
Placebo  138 (23.3)  152 (26.0)  126 (21.3)  165 (28.1)**  134 (22.6)  157 (26.8)  145 (24.5)  146 (24.8)
Diuretic  97 (16.4)  132 (22.5)*  95 (16.1)  134 (22.8)**  98 (16.5)  131 (22.3)*  105 (17.7)  124 (21.1)
Beta-blocker  44 (7.4)  59 (10.0)  47 (7.9)  56 (9.5)  45 (7.6)  58 (9.9)  51 (8.6)  52 (8.8)
dCCB  142 (24.0)  185 (31.5)**  145 (24.5)  182 (31.0)*  137 (23.1)  190 (32.4)***  160 (27.0)  167 (28.4) 
Sympatholytic  265 (44.8)  292 (49.7)  250 (42.2)  307 (52.2)***  256 (43.2)  301 (51.3)**  276 (46.6)  281 (47.8)
agent 
***p   0.001, **p   0.01, *p < 0.05 versus below. 
Abbreviations:  ACEi, angiotensin converting enzyme inhibitor; dCCB, dihydropyridine calcium channel blocker; ndCCB, non-dihydropyridine calcium channel blocker. 
Figure 4  In the BENEDICT study, the extent of systolic blood pressure (SBP) reduction had a speciﬁ  c and independent effect against the development of microalbuminuria.   
Angiotensin converting enzyme inhibitor (ACEi) therapy had a further protective effect, in particular when the SBP was less effectively controlled (inset).
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hypertension, and concern for compliance with multiple 
drugs is an issue. Since microalbuminuria is a strong predictor 
of kidney failure and cardiovascular morbidity/mortality, the 
speciﬁ  c protective effect of ACE inhibitor therapy against 
the development of microalbuminuria should be taken into 
consideration in treatment guidelines for the practising 
physician (Dinneen 1997; Ruggenenti et al 2006). Indeed, 
most guidelines recommend any agent in patients with dia-
betes and hypertension and without nephropathy, and only 
ACE inhibitors or angiotensin II receptor blockers once 
nephropathy occurs (National Kidney Foundation 2002). 
This largely rests on data from hypertension trials showing 
that blood pressure reduction limits cardiovascular morbid-
ity and mortality regardless of the antihypertensive agent 
used to achieve the target blood pressure, and overlooks that 
only ACE inhibitors have been proven to reduce the onset of 
microalbuminuria in hypertensive patients with diabetes. The 
post-hoc analysis of BENEDICT, consistent with previous 
evidence from BENEDICT (Ruggenenti et al 2004) and other 
trials (Strippoli et al 2005), provide the evidence that com-
pared with other agents, ACE inhibitors have an incremental 
beneﬁ  t on renal outcomes and so should be the treatment of 
choice in hypertensive patients with diabetes. 
Conclusion 
Effective blood pressure control and ACE inhibitor therapy 
are both key components of cardiovascular and renoprotective 
treatments in hypertensive type 2 diabetic patients. The com-
bination of an ACE inhibitor and an ndCCB may help achieve 
optimal blood pressure control while limiting the need for 
concomitant antihypertensive medications that may adversely 
affect the metabolic control and the overall cardiovascular risk 
proﬁ  le of people with diabetes. Trandolapril/verapamil SR is an 
effective and well tolerated combination therapy for both pa-
tients with hypertension and type 2 diabetes mellitus. In BENE-
DICT, trandolapril alone, or trandolapril/verapamil delayed 
the onset of microalbuminuria in more than 40% of patients 
compared with placebo in hypertensive diabetic patients. The 
effect of verapamil alone was similar to that of placebo. In the 
INVEST trial, ndCCB-based treatment strategy, in which most 
of the patients received ACE inhibitor (trandolapril), was more 
effective in reducing new onset diabetes in patients 50 years 
and older with hypertension and CAD. This indicates that the 
apparent advantage of ACE inhibitors over other antihyper-
tensive agents includes also a protective effect on the kidney 
against the development of microalbuminuria, at least in type 2 
diabetic patients, as well as development of new onset diabetes 
in hypertensive patients. Because microalbuminuria is a strong 
predictor of kidney failure and cardiovascular morbidity/
mortality, the speciﬁ  c protective effect of ACE inhibition 
therapy against the development of microalbuminuria should 
be taken into consideration in the treatment guidelines for the 
practising physician. Whether an antihypertensive regimen 
including such a combination drug may effectively limit the 
excess morbidity and mortality associated with type 2 diabetes 
is worth investigating in prospective randomized trials. 
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